Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Q1 2022 Earnings Presentation
7 slides from Pyc Therapeutics's earnings presentation, Mar 17, 2022
Slide 1: Life-changing science: 2022 Q1 investor call
For personal use only Life-changing 2022 Q1 investor call science 17 March 2022
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER For personal use only This presentation contains information about PYC Therapeutics Limited and its related bodies corporate (PYC) as at the date of this presentation. This presentation is for information purposes only and is not a prospectus or product disclosure sta
Slide 3: Q1 synthesis
For personal use only Q1 synthesis Strong progress within PYC, strong industry headwinds outside 3
Slide 4: PYC is progressing to a clinical-stage company in 2022
PYC is progressing to a clinical-stage company in 2022 For personal use only PYC’s immediate ambition is to become a platform Company with a clinically-validated technology • The three core milestones identified for 2022 to define the Company’s progression to a clinical-stage biotech were: 1. Establ
Slide 5: PYC's pipeline is expanding into high-value indications
PYC’s pipeline is expanding into high-value indications For personal use only PYC is expanding its pipeline of programs into additional high value targets both in the eye and beyond • The Company’s focus is on monogenic diseases due to: • The substantially higher probability of success in clinical d
Slide 6: Platform technologies with clinical validation are amongst the most sought-after assets
Platform technologies with clinical validation are amongst the most sought-after assets in the life sciences industry For personal use only Clinical validation Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001 PRPF31 RP11 PYC-001 OPA1 ADOA Discovery In 2022, PY
Slide 7: Q&A
For personal use only Q&A 7